S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

ICON Public (ICLR) Stock Price, News & Analysis

$292.02
-2.01 (-0.68%)
(As of 04/17/2024 ET)
Today's Range
$290.66
$296.93
50-Day Range
$269.06
$340.00
52-Week Range
$181.92
$344.77
Volume
386,144 shs
Average Volume
543,748 shs
Market Capitalization
$24.09 billion
P/E Ratio
39.57
Dividend Yield
N/A
Price Target
$319.45

ICON Public MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
9.4% Upside
$319.45 Price Target
Short Interest
Healthy
1.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of ICON Public in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.35%
From $14.40 to $16.61 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.97 out of 5 stars

Medical Sector

187th out of 914 stocks

Commercial Physical Research Industry

5th out of 11 stocks

ICLR stock logo

About ICON Public Stock (NASDAQ:ICLR)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

ICLR Stock Price History

ICLR Stock News Headlines

ICON Public (ICLR) to Release Quarterly Earnings on Wednesday
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Wawanesa Insurance Announces Wildfire Prevention Grant Recipients
ICON Announces CFO Transition
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
ICON Plc
ICLR Apr 2024 430.000 put
ICON plc to Present at Upcoming Investor Conferences
ICON Full Year 2023 Earnings: EPS Beats Expectations
Icon PLC (ICLR) Q4 Earnings Surpass Estimates
ICON Reports Fourth Quarter and Full Year 2023 Results
ICON Reports Fourth Quarter and Full Year 2023 Results
ICLR Apr 2024 380.000 call
See More Headlines
Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
4/17/2024
Next Earnings (Confirmed)
4/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:ICLR
Employees
41,100
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$319.45
High Stock Price Target
$367.00
Low Stock Price Target
$220.00
Potential Upside/Downside
+9.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$612.34 million
Pretax Margin
7.69%

Debt

Sales & Book Value

Annual Sales
$8.12 billion
Cash Flow
$19.00 per share
Book Value
$112.02 per share

Miscellaneous

Free Float
46,197,000
Market Cap
$24.09 billion
Optionable
Optionable
Beta
1.15

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. John Climax Ph.D. (Age 71)
    Founder & Independent Non-Executive Director
    Comp: $90k
  • Mr. Brendan Brennan (Age 45)
    Chief Financial Officer
    Comp: $1.07M
  • Dr. Steven A. Cutler MBA (Age 64)
    Ph.D., CEO & Director
    Comp: $2.54M
  • Jonathan Andrew Curtain (Age 48)
    Senior Vice President of Corporate & Commercial Finance
  • Mr. Thomas N. O'Leary
    Chief Information Officer
  • Mr. Diarmaid Cunningham (Age 49)
    Chief Administrative Officer, General Counsel & Company Secretary
  • Ms. Niamh Murphy
    Director of Corporate Communications
  • Mr. David Green
    Vice President of Marketing
  • Mr. Joe Cronin
    Chief Human Resources Officer
  • Mr. Simon Holmes (Age 57)
    President of Corporate Investments & Partnerships

Should I Buy ICON Public Stock? ICLR Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in ICON Public Limited:

  • ICON Public has shown consistent revenue growth over recent quarters, indicating a strong financial performance.
  • The company has a healthy return on equity of 11.42%, showcasing efficient utilization of shareholder funds.
  • Institutional investors have been increasing their stakes in ICON Public, reflecting confidence in the company's future prospects.
  • ICON Public's net margin of 7.54% demonstrates effective cost management and profitability.
  • Analysts expect ICON Public to post a solid EPS of 14.4 for the current fiscal year, suggesting potential for earnings growth.

Cons

Investors should be bearish about investing in ICON Public Limited for these reasons:

  • Despite strong financial metrics, the stock price of ICON Public may be overvalued based on current market conditions.
  • There could be regulatory risks associated with the clinical research industry that may impact ICON Public's operations and profitability.
  • Competition in the clinical research sector is intense, which could potentially affect ICON Public's market share and growth prospects.
  • Market volatility and economic uncertainties may pose challenges to ICON Public's stock performance in the short term.
  • Investors should carefully monitor any changes in industry trends and regulations that could impact ICON Public's business model and revenue streams.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these ICON Public pros and cons to contact@marketbeat.com.

ICLR Stock Analysis - Frequently Asked Questions

Should I buy or sell ICON Public stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ICLR shares.
View ICLR analyst ratings
or view top-rated stocks.

What is ICON Public's stock price target for 2024?

8 Wall Street research analysts have issued 1-year price objectives for ICON Public's shares. Their ICLR share price targets range from $220.00 to $367.00. On average, they predict the company's stock price to reach $319.45 in the next twelve months. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for ICLR
or view top-rated stocks among Wall Street analysts.

How have ICLR shares performed in 2024?

ICON Public's stock was trading at $283.07 at the start of the year. Since then, ICLR stock has increased by 3.2% and is now trading at $292.02.
View the best growth stocks for 2024 here
.

Are investors shorting ICON Public?

ICON Public saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 1,390,000 shares, a decline of 6.7% from the March 15th total of 1,490,000 shares. Based on an average trading volume of 551,500 shares, the short-interest ratio is presently 2.5 days. Currently, 1.7% of the company's shares are short sold.
View ICON Public's Short Interest
.

When is ICON Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our ICLR earnings forecast
.

How can I listen to ICON Public's earnings call?

ICON Public will be holding an earnings conference call on Thursday, April 25th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) announced its earnings results on Wednesday, February, 21st. The medical research company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.27 by $0.13. The medical research company earned $2.07 billion during the quarter, compared to analysts' expectations of $2.08 billion. ICON Public had a net margin of 7.54% and a trailing twelve-month return on equity of 11.42%.

What guidance has ICON Public issued on next quarter's earnings?

ICON Public updated its FY24 earnings guidance on Wednesday, April, 3rd. The company provided EPS guidance of $14.50-15.30 for the period, compared to the consensus estimate of $14.95. The company issued revenue guidance of $8.4-8.8 billion, compared to the consensus revenue estimate of $8.64 billion.

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public Chief Executive Officer Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among the company's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), Walt Disney (DIS), Home Depot (HD) and Johnson & Johnson (JNJ).

Who are ICON Public's major shareholders?

ICON Public's stock is owned by a variety of institutional and retail investors. Top institutional investors include Cullen Investment Group LTD. (0.01%), Steph & Co. (0.00%), NBC Securities Inc. (0.00%), GAMMA Investing LLC (0.00%) and Riverview Trust Co (0.00%).

How do I buy shares of ICON Public?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does ICON Public have any subsidiaries?
The following companies are subsidiares of ICON Public: Addplan Inc., Aptiv Solutions, Barton & Polansky Associates Inc., Beacon Bioscience Inc., BeijingWits Medical Consulting Ltd., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Research Management, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, Cross Country Healthcare - Clinical Trial Services, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Firecrest Clinical Ltd, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc., ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság, ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Group, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, MeDiNova Research, MedPass International, MediMedia Pharma Solutions, Molecular MD Corp., MolecularMD, Oxford Outcomes Limited, Oxford Outcomes Ltd, PMG Research, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, PRA Health Sciences, Pacific Research Associates Inc., Prevalere Life Sciences Inc., PriceSpective, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., Timaq Medical Imaging, UCT (U.S.) Inc, VSK (Kenilworth) Limited, and Veeda Laboratories Ltd..
Read More
This page (NASDAQ:ICLR) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners